{"id":949809,"date":"2026-04-08T08:06:18","date_gmt":"2026-04-08T12:06:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/american-college-of-cardiology-acc-scientific-sessions-2026-underscore-the-need-for-complementary-therapies-including-icosapent-ethyl-ipe-in-treatment-of-elevated-triglycerides-and-cardiovascular\/"},"modified":"2026-04-08T08:06:18","modified_gmt":"2026-04-08T12:06:18","slug":"american-college-of-cardiology-acc-scientific-sessions-2026-underscore-the-need-for-complementary-therapies-including-icosapent-ethyl-ipe-in-treatment-of-elevated-triglycerides-and-cardiovascular","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/american-college-of-cardiology-acc-scientific-sessions-2026-underscore-the-need-for-complementary-therapies-including-icosapent-ethyl-ipe-in-treatment-of-elevated-triglycerides-and-cardiovascular\/","title":{"rendered":"American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction"},"content":{"rendered":"
\n

DUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN) (\u201cAmarin\u201d), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today highlighted the important scientific and educational activities featured at the American College of Cardiology (ACC) Scientific Sessions 2026 that emphasized elevated and high triglycerides (TG) as a contributor to residual cardiovascular (CV) risk and the role that icosapent ethyl (IPE) plays in contemporary lipid and cardiovascular risk management.<\/p>\n

Scientific dialogue across the sessions consistently reinforced that substantial residual CV risk can persist in many patients beyond low-density lipoprotein cholesterol (LDL-C) control, highlighting the importance of implementing the updated and newly issued 2026 ACC\/American Heart Association (AHA)\/Multi-society Dyslipidemia Guidelines.i<\/sup> These guidelines recognize that elevated TG levels contribute meaningfully to CV disease burden and ongoing CV events even in patients achieving LDL-C targets, underscoring the need for complementary therapeutic approaches beyond statin monotherapy to further reduce risk in high and very high-risk populations.<\/p>\n

\n Amarin-Supported Scientific Presentations<\/strong>
\n
Amarin-supported abstracts presented at ACC Scientific Sessions 2026 included a new secondary, post hoc analysis from REDUCE-IT\u00ae titled \u201cEfficacy of Icosapent Ethyl Among Patients at Extreme Cardiovascular Risk: A Secondary Analysis of REDUCE-IT,\u201d presented by Dr. Rahul Aggarwal. The analysis evaluated outcomes with icosapent ethyl on top of statin therapy among patients at the highest levels of CV risk and concluded that IPE compared to placebo significantly reduced CV events in both extreme and very high-risk patient populations. The abstract can be accessed\u00a0here<\/a>.<\/p>\n

In addition, a poster titled \u201cRates of Lipoprotein(a) Oxidation Increase at Elevated Levels in a Non-Linear Fashion and Are Inhibited by Eicosapentaenoic Acid (EPA),\u201d presented by Dr. Samuel Sherratt, further explored biochemical pathways relevant to CV disease biology and EPA\u2019s potential mechanistic effects. The abstract can be accessed here<\/a>.<\/p>\n

\n Guideline and Late-Breaking Science Highlights<\/strong>
\n
Beyond Amarin-supported research, IPE was referenced during ACC guideline-focused programming in discussions addressing residual CV risk. These sessions emphasized that elevated triglycerides contribute meaningfully to CV event risk even among patients who have achieved LDL-C targets, underscoring the need for complementary and evidence-based therapeutic strategies beyond statin monotherapy.<\/p>\n

The newly released ACC\/AHA\/Multi-society Dyslipidemia Guidelines, along with other recent scientific statements,ii<\/sup>,<\/sup>iii<\/sup> also reiterated that fibrates are not recommended for routine use to reduce atherosclerotic cardiovascular disease (ASCVD) events due to inconsistent CV outcomes when added to statins.<\/p>\n

In a late-breaking clinical trials session, new data showed that substantial triglyceride lowering alone with an apoC3 inhibitor did not result in short\u2011term coronary plaque volume changes. Despite substantial reductions in triglycerides and remnant cholesterol, these changes were not consistently associated with reductions in coronary plaque volume,iv<\/sup> underscoring the complexity of residual CV risk and the need for outcomes and mechanistic evidence to assess long\u2011term clinical relevance.<\/p>\n

In prior published literature, IPE has demonstrated CV benefit in REDUCE\u2011ITv<\/sup>, with supportive mechanistic evidence from plaque imaging studies. EVAPORATEvi<\/sup> and CHERRYvii<\/sup> showed that treatment with IPE or eicosapentaenoic acid (EPA) was associated with favorable effects on coronary plaque characteristics over time. Together, these data suggest EPA\u2011based therapy may influence atherosclerotic disease biology beyond triglyceride lowering alone, helping to contextualize the potential mechanisms behind CV outcomes benefit observed with IPE on top of statin therapy.<\/p>\n

\u201cThe breadth of scientific discussion at ACC reflects a continued focus on residual cardiovascular risk and the importance of addressing lipid abnormalities beyond LDL\u2011C alone,\u201d said Steven Ketchum, PhD, President of Research & Development and Chief Scientific Officer at Amarin. \u201cAcross guideline updates, original research presentations, late\u2011breaking science sessions, and medical education programs, the REDUCE\u2011IT cardiovascular outcomes trial evidence base and the role of icosapent ethyl continue to be represented in discussions relevant to contemporary cardiovascular care.\u201d<\/p>\n

\n About Amarin<\/strong>
\n
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular care around the world.\u202f We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering close to 100 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world\u2019s leading cause of death, CVD.\u202f\u202f\u202f\u202f\u00a0<\/p>\n

\n About REDUCE-IT<\/strong>
\n
\n \u00ae
<\/strong>
\n <\/sup>REDUCE-IT was a global cardiovascular outcomes study designed to evaluate the effect of VASCEPA in adult patients with LDL-C controlled to between 41-100 mg\/dL (median baseline 75 mg\/dL) by statin therapy and various cardiovascular risk factors including persistent elevated triglycerides between 135-499 mg\/dL (median baseline 216 mg\/dL) and either established cardiovascular disease (secondary prevention cohort) or diabetes mellitus and at least one other cardiovascular risk factor (primary prevention cohort).<\/p>\n

REDUCE-IT, conducted over seven years and completed in 2018, followed 8,179 patients at over 400 clinical sites in 11 countries with the largest number of sites located within the United States. REDUCE-IT was conducted based on a special protocol assessment agreement with FDA. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.viii<\/sup> The primary results of REDUCE-IT were published in The New England Journal of Medicine in November 2018.v<\/sup> The total events results of REDUCE-IT were published in the Journal of the American College of Cardiology in March 2019.ix<\/sup> Dr. Bhatt serves as the Chair of the REDUCE-IT Steering Committee with research funding paid to Brigham and Women\u2019s Hospital and the Icahn School of Medicine at Mount Sinai.<\/p>\n

\n About Cardiovascular Risk<\/strong>
\n
Cardiovascular disease (CVD) is the number one cause of death in the world. In the United States alone, CVD – including heart disease, stroke, hypertension and heart failure – accounts for approximately 915,973 deaths per year, or about one death every 34 seconds.x<\/sup><\/p>\n

Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient\u2019s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.xi<\/sup> Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.xii<\/sup>,<\/sup>xiii<\/sup>,<\/sup>xiv<\/sup><\/p>\n

\n About VASCEPA\u00ae\/VAZKEPA\u00ae (icosapent ethyl) Capsules<\/strong>\u00a0
VASCEPA capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug\u2019s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (\u2265500 mg\/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty-five million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Australia, Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Bahrain, and Kuwait. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA is currently approved and sold in Europe in Sweden, Finland, England\/Wales, Spain, Netherlands, Scotland, Greece, Portugal, Italy, Denmark and Austria. \u00a0<\/p>\n

\n United States\u00a0Indications and Limitation of Use<\/strong>\u00a0
VASCEPA is\u00a0indicated:\u202f\u202f\u00a0<\/p>\n